10.52
0.33 (3.24%)
| Penutupan Terdahulu | 10.19 |
| Buka | 10.12 |
| Jumlah Dagangan | 1,656,095 |
| Purata Dagangan (3B) | 1,926,514 |
| Modal Pasaran | 1,369,827,968 |
| Harga / Pendapatan (P/E Ke hadapan) | 222.22 |
| Harga / Jualan (P/S) | 1.75 |
| Harga / Buku (P/B) | 1.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jul 2026 |
| Margin Keuntungan | -11.54% |
| Margin Operasi (TTM) | -16.56% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 68.08% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | 7.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.21 M |
| Pulangan Atas Aset (ROA TTM) | -2.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | NeoGenomics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.19% |
| % Dimiliki oleh Institusi | 98.21% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |